Confronting Deadly Diseases: Sabin’s Vaccine Trials for Sudan Ebolavirus and Marburg

Vaccines are our best defense against disease. Yet, we still have lethal diseases that need a vaccine solution urgently. Sabin's R&D team is tackling two such threats: Sudan ebolavirus and Marburg virus disease. There are no approved vaccines for either of these viruses which have left behind a trail of outbreaks, ending many lives and livelihoods in Africa. Sabin’s vaccines are in Phase 2 clinical trials in Uganda and Kenya. Initial results are expected next year. Findings from Phase 1 trials and studies were promising, suggesting these vaccines are safe, fast-acting, and robust.
Visit our website: www.sabin.org
-----
Follow Sabin!
LinkedIn: / sabin-vaccine-institute
Twitter: / sabinvaccine
Facebook: / sabinvaccine
Instagram: / sabinvaccine
Subscribe: www.sabin.org/newsletters/
-----
About the Sabin Vaccine Institute
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policymakers, and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.